BENETOR PLUS 20mg/12.5mg and 20mg/25mg film-coated tablets
- Name:
BENETOR PLUS 20mg/12.5mg and 20mg/25mg film-coated tablets
- Company:
Daiichi Sankyo Ireland Ltd
- Active Ingredients:
- Legal Category:
Product subject to medical prescription which may be renewed (B)
Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 09/06/20
(Click to Download) Summary of Product Characteristics last updated on medicines.ie: 9/6/2020
Click on this link to Download PDF directly
Daiichi Sankyo Ireland Ltd
Company Products
| Medicine Name | Active Ingredients |
|---|---|
| Medicine Name BENETOR 10mg, 20 mg and 40 mg film-coated tablets | Active Ingredients olmesartan medoxomil |
| Medicine Name BENETOR PLUS 20mg/12.5mg and 20mg/25mg film-coated tablets | Active Ingredients Hydrochlorothiazide, olmesartan medoxomil |
| Medicine Name Efient 5mg & 10mg film-coated tablets (Eli Lilly and Company Ltd Daiichi Sankyo UK Ltd) | Active Ingredients prasugrel hydrochloride |
| Medicine Name Evista | Active Ingredients Raloxifene |
| Medicine Name Lixiana Film-Coated Tablets | Active Ingredients Edoxaban tosilate |
Items Per Page :
1 - 0 of 5 items.Total: Infinity pages
When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.
Updated on 9 June 2020 SmPC
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.8 - Undesirable effects
Legal category: Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
Updated following Type IA Choroidal Effusion
Updated on 9 June 2020 PIL
Reasons for updating
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 4 - possible side effects
Free text change information supplied by the pharmaceutical company
Updated for Type IA Choroidal Effusion
Updated on 23 November 2018 PIL
Reasons for updating
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 4 - possible side effects
Updated on 22 November 2018 SmPC
Reasons for updating
- New SmPC for new product
Legal category: Product subject to medical prescription which may be renewed (B)
Updated on 23 December 2016 PIL
Reasons for updating
- New PIL for new product
Updated on 23 December 2016 PIL
Reasons for updating
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 4 - possible side effects
- Change to section 6 - date of revision
Updated on 22 July 2016 PIL
Reasons for updating
- Change to storage instructions
- Change to date of revision
Updated on 5 February 2015 PIL
Reasons for updating
- Change to warnings or special precautions for use
- Change to drug interactions
Updated on 17 November 2014 PIL
Reasons for updating
- Change to warnings or special precautions for use
Updated on 11 November 2014 PIL
Reasons for updating
- Change to warnings or special precautions for use
- Addition of information on reporting a side effect.
Updated on 28 July 2014 PIL
Reasons for updating
- Change to warnings or special precautions for use
- Change to storage instructions
- Change to side-effects
- Change to further information section
Updated on 21 December 2011 PIL
Reasons for updating
- Change due to harmonisation of PIL
Updated on 11 October 2011 PIL
Reasons for updating
- Improved electronic presentation
Updated on 21 April 2010 PIL
Reasons for updating
- Change of contraindications
- Change to side-effects
- Change to information about pregnancy or lactation
- Change to marketing authorisation holder
Updated on 26 September 2006 PIL
Reasons for updating
- Improved electronic presentation
Updated on 6 September 2006 PIL
Reasons for updating
- Correction of spelling/typing errors
Updated on 4 September 2006 PIL
Reasons for updating
- New PIL for new product